Abstract
Aims Intramyocardial inflammation is considered an adverse prognostic factor in inflammatory cardiomyopathy (CMi). However, the precise nature of immune system factors relevant for the prediction of long-term course remains elusive. The aim of this study was to analyse the prognostic relevance of perforin in a large cohort of patients with CMi. Methods and results We investigated 495 consecutive patients with suspected CMi, undergoing endomyocardial biopsies (EMBs), and examined haemodynamic measurements after a long follow-up period (interquartile range 10.2-37.1-months). In EMBs, myocardial inflammation was assessed by histology and immunohistology. At follow-up, 388 patients (Group I) showed stable mild dysfunction or significant improvement, with LVEF rising from 46.2-±-14.8% to 64.3-±-12.3% (P-
Author supplied keywords
Cite
CITATION STYLE
Escher, F., Kühl, U., Lassner, D., Stroux, A., Westermann, D., Skurk, C., … Schultheiss, H. P. (2014). Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. European Journal of Heart Failure, 16(10), 1066–1072. https://doi.org/10.1002/ejhf.148
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.